Dengue Vaccine Market Estimated to Grow at a CAGR of 17.5% During Forecast Period 2017-2027
The global dengue vaccine market is projected to be valued at more than US$ 1250 Mn by 2027.
Albany, NY -- (SBWire) -- 05/21/2019 --The expanding database of Market Research Reports Search Engine (MRRSE) has been recently updated by the addition of a new study which is titled as "Dengue Vaccine Market Estimated to Grow at a CAGR of 17.5% during Forecast Period 2017- 2027". The fact-based research report on the global Dengue Vaccine market covers various aspects such as trends, drivers, challenges and opportunities that have an influence on the growth and expansion of the global market. All these factors are analyzed across key regions of Latin America, North America, Europe, Middle and Africa (MEA) and the Asia Pacific. In order to provide an accurate forecast, analysts have presented the current market, which forms the basis of how the metal caps and closures market is expected to develop in the future.
Request Free Sample Report @ https://www.mrrse.com/sample/3038
The first dengue vaccine, Dengvaxia (CYD-TDV) developed by Sanofi Pasteur is registered in 14 countries in the Latin America and Asia Pacific region. CYD-TDV vaccine is a live recombinant tetravalent dengue vaccine that is indicated as a 3 dose series of 0/6/12 month schedule. There are around five other vaccine candidates under evaluation in clinical trials, comprising other live-attenuated vaccines as well as subunit, DNA and purified inactivated vaccine candidates of which Takeda's TAK-003 and Butantan Institute vaccine candidates are being evaluated in phase 3 clinical trials currently.
he global dengue vaccine market is estimated to be valued at nearly US$ 250 Mn in 2017 and is expected to expand at a 17.5% CAGR over the forecast period (2017–2027). The global dengue vaccine market is projected to be valued at more than US$ 1250 Mn by 2027.
Factors impacting the global dengue vaccine market
Growth of the global dengue vaccine market is mainly driven by rising burden of dengue fever in tropical regions, large unmet medical need for managing dengue burden, promising end stage vaccine pipeline, development of live attenuated tetravalent dengue vaccine, and expected local production of dengue vaccine in various countries. Other prominent factors driving revenue growth of the market are adoption/uptake of dengue vaccine by various countries in dengue endemic regions of Latin America and Asia Pacific and increased governmental interest to incorporate the vaccine in public immunisation programmes across various countries.
However, supply side infrastructure bottlenecks such as surveillance system, standardised diagnostics practice, and cold chain systems for storage of vaccine in resource constrained countries are the factors hampering the growth of the global dengue vaccine market.
Companies engaged in the development of dengue vaccine are employing strategies to incorporate dengue vaccine in public immunisation programmes and vaccines in clinical stage development are being tested for safety and efficacy in all age groups and different transmission settings.
Browse Complete Report with TOC @ https://www.mrrse.com/dengue-vaccines-market
Several governments are willing to incorporate dengue vaccine in public immunisation programmes given assured quality, safety and affordability of the vaccine in endemic countries
The Government Institutes segment is expected to dominate the global dengue vaccine market in revenue terms and the trend is projected to continue throughout the forecast period. The Government Institutes segment is estimated to account for 49.5% value share in 2017 and is projected to account for 51.9% share by the end of 2027. In terms of value, the Hospitals segment is anticipated to register a moderate CAGR of 17.3% during the forecast period. The NGOs segment is expected to remain the least attractive segment in the global dengue vaccine market in revenue terms with an attractiveness index of 0.7 over the forecast period. The NGOs segment is estimated to account for 22.5% value share in 2017 and is projected to account for 20.5% value share by the end of 2027. Analyst Viewpoint
Developing a vaccine that is effective in all age groups is expected to drive market revenue growth over the forecast period
Of late dengue vaccine candidates, which are in the late stage of development, are showing better clinical benefits in all age groups and have better dosing pattern. For instance, Takeda's - Tak-003 dengue vaccine candidate has demonstrated acceptable safety and efficacy in different population groups with two doses (three months apart) of vaccine. Currently Dengvaxia is recommended in three doses at 0, 6, 12 months. Development of dengue vaccine that is effective for infants and children is expected to reduce the dengue burden and thereby create demand in the global dengue vaccine market.
Enquire about this Report @ https://www.mrrse.com/enquiry/3038
About Market Research Reports Search Engine (MRRSE)
Market Research Reports Search Engine (MRRSE) is an industry-leading database of Market Research Reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE's repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
Contact Us
State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States Telephone: +1-518-730-0559
Email: sales@mrrse.com
Media Relations Contact
Himanshu
Manager
MRRSE
1-518-621-2074
https://www.mrrse.com/
View this press release online at: http://rwire.com/1220440